Q: What is Ibsrela used for?

Ibsrela is used to treat irritable bowel syndrome with constipation .

Q: How does Ibsrela work?

Mechanism of Action Ibsrela contains the active ingredient tenapanor, which belongs to a class of medications called sodium-hydrogen exchanger 3 (NHE3) inhibitors. Unlike many other medications, it acts locally within the gastrointestinal tract and is not significantly absorbed into the bloodstream. How It Relieves Constipation The medication works by blocking the NHE3 transporter, a protein found on the surface of the small intestine and colon. This protein is responsible for absorbing sodium from the gut. When this process is blocked: Sodium remains inside the intestines instead of being absorbed. The presence of extra sodium causes water to move into the intestines through a process called osmosis. The increased water content softens the stool and adds bulk, which helps the stool move through the digestive system more quickly and frequently. How It Relieves Pain In addition to its effects on bowel movements, Ibsrela is thought to help reduce abdominal pain. It may do this by decreasing the sensitivity of the nerves in the gut that transmit pain signals. This helps lower the overall discomfort often experienced by people with irritable bowel syndrome with constipation (IBS-C).

Q: What are the active ingredients in Ibsrela?

The active ingredient in Ibsrela is tenapanor .

Q: What are the side effects of Ibsrela?

Common side effects of Ibsrela may include: diarrhea abdominal pain bloating Always consult with a healthcare professional about potential side effects.

Q: What drug class is Ibsrela?

Ibsrela belongs to the NHE3 inhibitor drug class.

Q: What is the dosage of Ibsrela and how do I take it?

How to Take Ibsrela Ibsrela is taken by mouth. To ensure the medication works correctly, follow these instructions: Take the medication twice a day. Take your first dose immediately before breakfast or the first meal of the day. Take your second dose immediately before dinner. Swallow the tablets whole. Do not crush or chew the medication. Missed Dose If you miss a dose, skip it and take your next dose at the regular time. Do not take two doses at the same time to make up for a missed dose.

Q: Is Ibsrela safe during pregnancy and breastfeeding?

Pregnancy There is currently limited data on the use of Ibsrela during pregnancy. Because the medication is minimally absorbed into the bloodstream from the digestive tract, it is unlikely that a developing fetus would be exposed to the drug. Research in animals using doses much higher than the recommended human dose did not show evidence of harm to the fetus. Pregnant individuals should discuss the potential risks and benefits of treatment with their healthcare provider. Breastfeeding It is unknown whether Ibsrela is present in human breast milk or if it has any effect on a nursing infant or milk production. Since the drug is not well-absorbed into the body, exposure to a breastfed infant is expected to be very low. Patients are encouraged to talk with their healthcare provider about the use of this medication while breastfeeding to determine the best course of action for both the parent and the child.

Q: What forms and strengths does Ibsrela come in?

Ibsrela is supplied in the following form: Oral Tablet: This medication is a film-coated tablet intended for oral administration. The tablets are packaged in bottles that include a desiccant canister to protect the medicine from moisture. It is recommended to keep the tablets in their original container with the desiccant and to keep the bottle tightly closed.

Q: What is the FDA approval status of Ibsrela?

FDA Approval and Indications The U.S. Food and Drug Administration (FDA) approved Ibsrela (tenapanor) in September 2019. It is specifically indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in adult patients. Boxed Warning Ibsrela carries a Boxed Warning, the FDA’s most serious category of warning, due to the risk of severe dehydration in pediatric patients. The following restrictions apply: Contraindication: Ibsrela is contraindicated in children under the age of 6 years. In clinical studies involving young rats (standardized to human age equivalents), the medication caused deaths related to dehydration. Avoidance in Older Children: The FDA recommends avoiding the use of Ibsrela in patients aged 6 years to less than 18 years, as the safety and effectiveness of the drug have not been established for this age group. Regulatory Status Ibsrela is a prescription-only medication and is not available over-the-counter. It is classified as a sodium-hydrogen exchanger 3 (NHE3) inhibitor. The FDA has not approved this medication for use in children or for any conditions other than IBS-C.

Question 1

What is Ibsrela?

Accepted Answer

Ibsrela is a medication classified as a sodium-hydrogen exchanger 3 (NHE3) inhibitor. It acts locally within the gastrointestinal tract to decrease the absorption of sodium in the small intestine and colon.

The reduction of sodium absorption leads to an increase in water secretion into the intestinal lumen. This mechanism helps to soften the consistency of stool and promotes more frequent bowel movements by accelerating intestinal transit time.

Question 2

What is Ibsrela used for?

Accepted Answer

Ibsrela is used to treat irritable bowel syndrome with constipation.

Question 3

How does Ibsrela work?

Accepted Answer

Mechanism of Action

Ibsrela contains the active ingredient tenapanor, which belongs to a class of medications called sodium-hydrogen exchanger 3 (NHE3) inhibitors. Unlike many other medications, it acts locally within the gastrointestinal tract and is not significantly absorbed into the bloodstream.

How It Relieves Constipation

The medication works by blocking the NHE3 transporter, a protein found on the surface of the small intestine and colon. This protein is responsible for absorbing sodium from the gut. When this process is blocked:

Sodium remains inside the intestines instead of being absorbed.
The presence of extra sodium causes water to move into the intestines through a process called osmosis.
The increased water content softens the stool and adds bulk, which helps the stool move through the digestive system more quickly and frequently.

How It Relieves Pain

In addition to its effects on bowel movements, Ibsrela is thought to help reduce abdominal pain. It may do this by decreasing the sensitivity of the nerves in the gut that transmit pain signals. This helps lower the overall discomfort often experienced by people with irritable bowel syndrome with constipation (IBS-C).

Question 4

What are the active ingredients in Ibsrela?

Accepted Answer

The active ingredient in Ibsrela is tenapanor.

Question 5

What are the side effects of Ibsrela?

Accepted Answer

Common side effects of Ibsrela may include:

diarrhea
abdominal pain
bloating

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Ibsrela?

Accepted Answer

Ibsrela belongs to the NHE3 inhibitor drug class.

Question 7

What is the dosage of Ibsrela and how do I take it?

Accepted Answer

How to Take Ibsrela

Ibsrela is taken by mouth. To ensure the medication works correctly, follow these instructions:

Take the medication twice a day.
Take your first dose immediately before breakfast or the first meal of the day.
Take your second dose immediately before dinner.
Swallow the tablets whole. Do not crush or chew the medication.

Missed Dose

If you miss a dose, skip it and take your next dose at the regular time. Do not take two doses at the same time to make up for a missed dose.

Question 8

Is Ibsrela safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

There is currently limited data on the use of Ibsrela during pregnancy. Because the medication is minimally absorbed into the bloodstream from the digestive tract, it is unlikely that a developing fetus would be exposed to the drug. Research in animals using doses much higher than the recommended human dose did not show evidence of harm to the fetus. Pregnant individuals should discuss the potential risks and benefits of treatment with their healthcare provider.

Breastfeeding

It is unknown whether Ibsrela is present in human breast milk or if it has any effect on a nursing infant or milk production. Since the drug is not well-absorbed into the body, exposure to a breastfed infant is expected to be very low. Patients are encouraged to talk with their healthcare provider about the use of this medication while breastfeeding to determine the best course of action for both the parent and the child.

Question 9

What forms and strengths does Ibsrela come in?

Accepted Answer

Ibsrela is supplied in the following form:

Oral Tablet: This medication is a film-coated tablet intended for oral administration.

The tablets are packaged in bottles that include a desiccant canister to protect the medicine from moisture. It is recommended to keep the tablets in their original container with the desiccant and to keep the bottle tightly closed.

Question 10

What is the FDA approval status of Ibsrela?

Accepted Answer

FDA Approval and Indications

The U.S. Food and Drug Administration (FDA) approved Ibsrela (tenapanor) in September 2019. It is specifically indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in adult patients.

Boxed Warning

Ibsrela carries a Boxed Warning, the FDA’s most serious category of warning, due to the risk of severe dehydration in pediatric patients. The following restrictions apply:

Contraindication: Ibsrela is contraindicated in children under the age of 6 years. In clinical studies involving young rats (standardized to human age equivalents), the medication caused deaths related to dehydration.
Avoidance in Older Children: The FDA recommends avoiding the use of Ibsrela in patients aged 6 years to less than 18 years, as the safety and effectiveness of the drug have not been established for this age group.

Regulatory Status

Ibsrela is a prescription-only medication and is not available over-the-counter. It is classified as a sodium-hydrogen exchanger 3 (NHE3) inhibitor. The FDA has not approved this medication for use in children or for any conditions other than IBS-C.

Question 11

What should I know about Ibsrela and cost?

Accepted Answer

Insurance Coverage

The amount you pay for Ibsrela depends largely on your health insurance plan. Many insurance providers require prior authorization, which means your doctor must provide additional information to the insurance company before the drug is covered. Your specific co-pay or co-insurance will depend on your plan's formulary tier for this medication.

Retail Price

For those paying out-of-pocket, the retail price for a standard 30-day supply of 50 mg tablets is approximately $1,800. Prices can vary between different retail and mail-order pharmacies.

Financial Assistance Programs

There are options available to help manage the cost of Ibsrela:

Savings Cards: The manufacturer may provide a savings card for patients with commercial insurance to help lower monthly co-pays.
Patient Assistance: Programs may be available for individuals who are uninsured or meet specific financial criteria to receive the medication at a lower cost.

Patients are encouraged to contact their insurance provider or the manufacturer's support program to determine their specific costs and eligibility for financial aid.

Ibsrela

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Ibsrela

Hospitals.net Disclosure